{
  "ticker": "PTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969447",
  "id": "02969447",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250715",
  "time": "1301",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250715/pdf/06ltbl3trtvxq2.pdf",
  "summary": "- **Announcement Type**: Update to previous announcement (Securities Purchase Plan - SPP)  \n- **Key Change**: Extension of closing date to **22 July 2025** (previously 15 July 2025).  \n- **SPP Details**:  \n  - **Offer Price**: AUD 0.04 per share.  \n  - **Maximum Shares Issuable**: 175,000,000 (up to AUD 7 million).  \n  - **Subscription Limits**: AUD 5,000 minimum / AUD 30,000 maximum per eligible shareholder (Australia/NZ only).  \n  - **Use of Proceeds**: Phase 2 clinical development of PTX-100 (cancer therapy) and working capital.  \n- **Broker Fees**: 6% of funds raised + call options (1:20 ratio, strike AUD 0.06, 4-year expiry).  \n- **Timetable**:  \n  - Record Date: 30 June 2025.  \n  - Issue Date: 30 July 2025.  \n\n*Omitted non-material details: Director names, legal boilerplate, non-eligible jurisdictions.*",
  "usage": {
    "prompt_tokens": 2213,
    "completion_tokens": 239,
    "total_tokens": 2452,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-15T04:12:26.283018"
}